SAR131675, a VEGRF3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis
Most patients with colorectal cancer (CRC) develop metastases, predominantly in the liver (CLM). Targeted therapies are being investigated to improve current CLM treatments. This study tested the effectiveness of SAR131675, a selective VEGFR-3 tyrosine kinase inhibitor, to inhibit CLM in a murine mo...
Main Authors: | Katrina A. Walsh, Georgios Kastrappis, Theodora Fifis, Rita Paolini, Christopher Christophi, Marcos V. Perini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/11/2715 |
Similar Items
-
Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells
by: Nicolas Espagnolle, et al.
Published: (2014-02-01) -
BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma
by: Mehreen Ishfaq, et al.
Published: (2021-02-01) -
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
by: Daniele Lavacchi, et al.
Published: (2023-03-01) -
Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis
by: Megan Stevens, et al.
Published: (2019-03-01) -
Angiogenesis—An Emerging Role in Organ Fibrosis
by: Dan Wang, et al.
Published: (2023-09-01)